Liver Cancer Diagnostics Market: Global Industry Analysis and Forecast (2024-2030) by Test Type, End-use, and, Region.

Liver Cancer Diagnostics Market size was valued at US$ 12.04 Billion in 2023 and the Liver Cancer Diagnostics revenue is expected to grow at 7.5% through 2024 to 2030, reaching nearly US$ 19.97 Billion.

Format : PDF | Report ID : SMR_268

Liver Cancer Diagnostics Market Definition & Overview:

Liver cancer is one of the top causes of cancer mortality worldwide. According to the American Cancer Society, the incidence of liver cancer has more than quadrupled in the last few decades, and the fatality rate has more than doubled. According to the same source, about 42,230 new cases of liver cancer detected in the United States in 2021, resulting in approximately 30,230 fatalities. Chronic viral hepatitis, Cirrhosis, high alcohol intake, cigarette use, and obesity are all key risk factors for this condition. Early detection and identification of liver cancer are critical for reducing mortality, creating a strong need for novel diagnostic tools. Liver Cancer Diagnostics Market's segment analysis is studied on the basis of test type, end use and region.

Liver Cancer Diagnostics Market

To get more Insights: Request Free Sample Report

Liver Cancer Diagnostics Market Dynamics:

According to Globocan statistics, liver cancer was the 6th most frequent kind of cancer in 2020, with around 905,677 new instances of this life-threatening disease being identified globally, resulting in approximately 830,180 fatalities. Chronic (long-term) infection with Hepatitis C Virus (HCV) or Hepatitis B Virus is the most prevalent cause of liver cancer (HBV). According to WHO estimates, 71.0 million persons worldwide have chronic HCV infection. According to the same source, over 399,000 persons died in 2016 as a result of cirrhosis and primary liver cancer caused by HCV infection. Because of the disease's high incidence and death rate, the need for novel diagnostic methods for prompt diagnosis has increased dramatically, driving the liver cancer diagnostics market growth.

Additionally, an increase in the number of initiatives aimed at raising awareness about early detection of liver cancer is likely to be a major driver driving up demand for its diagnostic tools globally. The National Cancer Institute (NCI) supported a research study at Michigan Medicine in 2018 to improve liver cancer monitoring and early diagnosis in the United States. Collaborations and partnerships between the National Cervical Cancer Coalition, the World Health Organization, the Centers for Disease Control and Prevention, the United States Preventive Services Task Force, and others to increase liver cancer screening are also expected to boost liver cancer diagnostics market growth during the forecast period.

Liver Cancer Diagnostics Market Segment Analysis:

The laboratory tests segment dominated the liver cancer diagnostics market in 2023, accounting for 39.5 percent of total revenue. During the forecast period, the segment is expected to increase at the quickest rate. The strong preference for laboratory tests owing to their correctness and cost-efficiency can be linked to their big market and growth. Laboratory tests are also used to assess high-risk individuals, determine therapy options, determine disease stages, and determine how well the illness is responding to treatment.

Over the forecast period, hospital-affiliated laboratories are estimated to account for the vast majority of revenue in the worldwide liver cancer diagnostics business. Increasing emphasis on operations that need a medical setting and tests that require hospitalization, as well as increased demand for biopsy for liver cancer diagnostics, are some of the primary reasons driving liver cancer diagnostics market expansion for hospital-associated labs.

Liver Cancer Diagnostics Market Regional Insights:

North America dominated the liver cancer diagnostics market in 2023, accounting for 40.1 percent of total revenue, and is expected to continue to do so throughout the forecast period. This region's dominance is due to its well-established healthcare infrastructure, effective health-insurance policies, and widespread use of modern diagnostic technologies. Because of the greater frequency of hepatocellular carcinoma and strong knowledge about early diagnosis, the United States controls the market share in North America. In the United States, Market size was valued at US$ 8.2 billion in 2020.

The liver cancer diagnostics market in the Asia Pacific is expected to grow at the fastest rate throughout the research period. The high frequency of hepatitis in developing countries such as India and China is responsible for this rapid development. Increased government attempts to raise awareness about early identification of liver cancer, as well as increased alcohol and cigarette usage in the region, are further factors impacting the market growth.

China, the world's second-biggest economy, is expected to reach a market size of US$9.1 million by 2030, with an annual growth rate of 8.3% from 2020 to 2027. Japan and Canada are two more important geographic markets, with forecasted growth rates of 2.9 percent and 4.8 percent, respectively, from 2020 to 2027. Germany is expected to expand at a CAGR of around 3.3 percent in Europe.

The objective of the report is to present a comprehensive analysis of the Liver Cancer Diagnostics Market to the stakeholders in the industry. The report provides trends that are most dominant in the Liver Cancer Diagnostics Market and how these trends will influence new business investments and market development throughout the forecast period. The report also aids in the comprehension of the global market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.

The qualitative and quantitative data provided in the Liver Cancer Diagnostics Market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Liver Cancer Diagnostics Market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the global market.

The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Liver Cancer Diagnostics Market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.

Liver Cancer Diagnostics Market Scope:

Liver Cancer Diagnostics Market
Market Size in 2023	USD 12.04 Bn.
Market Size in 2030	USD 19.97 Bn.
CAGR (2024-2030)	7.5%
Historic Data	2018-2022
Base Year	2023
Forecast Period	2024-2030
Segment Scope	by Test Type Laboratory Tests Biomarkers Oncofetal and Glycoprotein Antigens Enzymes and Isoenzymes Growth Factors and Receptors Molecular Markers Pathological Biomarkers Blood Tests Imaging Tests Endoscopy Biopsy Others
Segment Scope	By End-use Hospitals & Diagnostic Laboratories Academic & Research Institutes Pharmaceutical & CRO Laboratories
Regional Scope	North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

Liver Cancer Diagnostics Market Players:

Abbott Laboratories (United States)
F. Hoffmann-La Roche Ltd. (Switzerland)
Qiagen N.V. (Germany)
Thermo Fisher Scientific, Inc. (United States)
Siemens Healthineers (Germany)
Becton Dickinson & Company (United States)
Illumina, Inc. (United States)
Koninklijke Philips N.V. (Netherlands)
Epigenomics AG (Germany)
Fujifilm Medical Systems U.S.A., Inc. (United States)
Hologic, Inc. (United States)
Thermo Fisher Scientific, Inc. (United States)
Biocept, Inc. (United States)
Danaher (United States)
Foundation Medicine, Inc., (United States)

Buy Now

Request For Free sample

Frequently Asked Questions

What is the projected market size & growth rate of the Liver Cancer Diagnostics Market?

the Liver Cancer Diagnostics Market size was valued at US$ 9.7 Billion in 2020 and the Liver Cancer Diagnostics revenue is expected to grow at 7.5% through 2024 to 2030, reaching nearly US$ 19.97 Billion.

What are the key driving factor for the growth of the Liver Cancer Diagnostics Market?

disease's high incidence and death rate, the need for novel diagnostic methods for prompt diagnosis has increased dramatically, driving the market growth.

Which Region accounted for the largest Liver Cancer Diagnostics Market share?

North America dominated the liver cancer diagnostics market in 2020, accounting for 40.1 percent of total revenue, and is expected to continue to do so throughout the forecast period.

What makes Asia Pacific a Lucrative Market for Liver Cancer Diagnostics Market?

The high frequency of hepatitis in developing countries such as India and China is responsible for this rapid development.

What are the top players operating in Liver Cancer Diagnostics Market?

Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V., Thermo Fisher Scientific, Inc., Siemens Healthineers, and Becton Dickinson & Company.

1.   Research Methodology
1.1   Research Data
1.1.1.   Primary Data
1.1.2.   Secondary Data
1.2.   Market Size Estimation
1.2.1.   Bottom-Up Approach
1.2.2.   Top-Up Approach
1.3.   Market Breakdown and Data Triangulation
1.4.   Research Assumption

2.   Liver Cancer Diagnostics Market Executive Summary
2.1.   Market Overview
2.2.   Market Size (2023) and Forecast (2024 – 2030) and Y-O-Y%
2.3.   Market Size (USD) and Market Share (%) – By Segments and Regions

3.   Global Liver Cancer Diagnostics Market: Competitive Landscape
3.1.   SMR Competition Matrix
3.2.   Key Players Benchmarking
3.2.1.   Company Name
3.2.2.   Headquarter
3.2.3.   Service Segment
3.2.4.   End-user Segment
3.2.5.   Y-O-Y%
3.2.6.   Revenue (2023)
3.2.7.   Market Share
3.2.8.   Company Locations
3.3.   Market Structure
3.3.1.   Market Leaders
3.3.2.   Market Followers
3.3.3.   Emerging Players
3.4.   Consolidation of the Market
3.4.1.   Strategic Initiatives and Developments
3.4.2.   Mergers and Acquisitions
3.4.3.   Collaborations and Partnerships

4.   Liver Cancer Diagnostics Market: Dynamics
4.1.   Liver Cancer Diagnostics Market Trends by Region
4.1.1.   North America
4.1.2.   Europe
4.1.3.   Asia Pacific
4.1.4.   Middle East and Africa
4.1.5.   South America
4.2.   Liver Cancer Diagnostics Market Drivers
4.3.   Liver Cancer Diagnostics Market Restraints
4.4.   Liver Cancer Diagnostics Market Opportunities
4.5.   Liver Cancer Diagnostics Market Challenges
4.6.   PORTER’s Five Forces Analysis
4.6.1.   Intensity of the Rivalry
4.6.2.   Threat of New Entrants
4.6.3.   Bargaining Power of Suppliers
4.6.4.   Bargaining Power of Buyers
4.6.5.   Threat of Substitutes
4.7.   PESTLE Analysis
4.7.1.   Political Factors
4.7.2.   Economic Factors
4.7.3.   Social Factors
4.7.4.   Legal Factors
4.7.5.   Environmental Factors
4.8.   Technological Roadmap
4.9.   Regulatory Landscape
4.9.1.   Market Regulation by Region
4.9.1.1.   North America
4.9.1.2.   Europe
4.9.1.3.   Asia Pacific
4.9.1.4.   Middle East and Africa
4.9.1.5.   South America
4.9.2.   Impact of Regulations on Market Dynamics
4.9.3.   Government Schemes and Initiatives

5.   Liver Cancer Diagnostics Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
5.1.   Liver Cancer Diagnostics Market Size and Forecast, by Test Type (2023-2030)
5.1.1.   Laboratory Tests
5.1.2.   Biomarkers
5.1.3.   Oncofetal and Glycoprotein Antigens
5.1.4.   Enzymes and Isoenzymes
5.1.5.   Growth Factors and Receptors
5.1.6.   Molecular Markers
5.1.7.   Pathological Biomarkers
5.1.8.   Blood Tests
5.1.9.   Imaging Tests
5.1.10.   Endoscopy
5.1.11.   Biopsy
5.1.12.   Others
5.2.   Liver Cancer Diagnostics Market Size and Forecast, by End Use (2023-2030)
5.2.1.   Hospitals & Diagnostic Laboratories
5.2.2.   Academic & Research Institutes
5.2.3.   Pharmaceutical & CRO Laboratories
5.3.   Liver Cancer Diagnostics Market Size and Forecast, by Region (2023-2030)
5.3.1.   North America
5.3.2.   Europe
5.3.3.   Asia Pacific
5.3.4.   Middle East and Africa
5.3.5.   South America

6.   North America Liver Cancer Diagnostics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
6.1.   North America Liver Cancer Diagnostics Market Size and Forecast, by Test Type (2023-2030)
6.1.1.   Laboratory Tests
6.1.2.   Biomarkers
6.1.3.   Oncofetal and Glycoprotein Antigens
6.1.4.   Enzymes and Isoenzymes
6.1.5.   Growth Factors and Receptors
6.1.6.   Molecular Markers
6.1.7.   Pathological Biomarkers
6.1.8.   Blood Tests
6.1.9.   Imaging Tests
6.1.10.   Endoscopy
6.1.11.   Biopsy
6.1.12.   Others
6.2.   North America Liver Cancer Diagnostics Market Size and Forecast, by End Use (2023-2030)
6.2.1.   Hospitals & Diagnostic Laboratories
6.2.2.   Academic & Research Institutes
6.2.3.   Pharmaceutical & CRO Laboratories
6.3.   North America Liver Cancer Diagnostics Market Size and Forecast, by Country (2023-2030)
6.3.1.   United States
6.3.2.   Canada
6.3.3.   Mexico

7.   Europe Liver Cancer Diagnostics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
7.1.   Europe Liver Cancer Diagnostics Market Size and Forecast, by Test Type (2023-2030)
7.2.   Europe Liver Cancer Diagnostics Market Size and Forecast, by End Use (2023-2030)
7.3.   Europe Liver Cancer Diagnostics Market Size and Forecast, by Country (2023-2030)
7.3.1.   United Kingdom
7.3.2.   France
7.3.3.   Germany
7.3.4.   Italy
7.3.5.   Spain
7.3.6.   Sweden
7.3.7.   Austria
7.3.8.   Rest of Europe

8.   Asia Pacific Liver Cancer Diagnostics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
8.1.   Asia Pacific Liver Cancer Diagnostics Market Size and Forecast, by Test Type (2023-2030)
8.2.   Asia Pacific Liver Cancer Diagnostics Market Size and Forecast, by End Use (2023-2030)
8.3.   Asia Pacific Liver Cancer Diagnostics Market Size and Forecast, by Country (2023-2030)
8.3.1.   China
8.3.2.   S Korea
8.3.3.   Japan
8.3.4.   India
8.3.5.   Australia
8.3.6.   Indonesia
8.3.7.   Malaysia
8.3.8.   Vietnam
8.3.9.   Taiwan
8.3.10.   Rest of Asia Pacific

9.   Middle East and Africa Liver Cancer Diagnostics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
9.1.   Middle East and Africa Liver Cancer Diagnostics Market Size and Forecast, by Test Type (2023-2030)
9.2.   Middle East and Africa Liver Cancer Diagnostics Market Size and Forecast, by End Use (2023-2030)
9.3.   Middle East and Africa Liver Cancer Diagnostics Market Size and Forecast, by Country (2023-2030)
9.3.1.   South Africa
9.3.2.   GCC
9.3.3.   Nigeria
9.3.4.   Rest of ME&A

10.   South America Liver Cancer Diagnostics Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030)
10.1.   South America Liver Cancer Diagnostics Market Size and Forecast, by Test Type (2023-2030)
10.2.   South America Liver Cancer Diagnostics Market Size and Forecast, by End Use (2023-2030)
10.3.   South America Liver Cancer Diagnostics Market Size and Forecast, by Country (2023-2030)
10.3.1.   Brazil
10.3.2.   Argentina
10.3.3.   Rest Of South America

11.   Company Profile: Key Players
11.1.   Abbott Laboratories (United States)
11.1.1.   Company Overview
11.1.2.   Business Portfolio
11.1.3.   Financial Overview
11.1.3.1.   Total Revenue
11.1.3.2.   Segment Revenue
11.1.3.3.   Regional Revenue
11.1.4.   SWOT Analysis
11.1.5.   Strategic Analysis
11.1.6.   Recent Developments
11.2.   F. Hoffmann-La Roche Ltd. (Switzerland)
11.3.   Qiagen N.V. (Germany)
11.4.   Thermo Fisher Scientific, Inc. (United States)
11.5.   Siemens Healthineers (Germany)
11.6.   Becton Dickinson & Company (United States)
11.7.   Illumina, Inc. (United States)
11.8.   Koninklijke Philips N.V. (Netherlands)
11.9.   Epigenomics AG (Germany)
11.10.   Fujifilm Medical Systems U.S.A., Inc. (United States)
11.11.   Hologic, Inc. (United States)
11.12.   Thermo Fisher Scientific, Inc. (United States)
11.13.   Biocept, Inc. (United States)
11.14.   Danaher (United States)
11.15.   Foundation Medicine, Inc., (United States)